Does OSIMERTINIB Cause Neoplasm malignant? 165 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 165 reports of Neoplasm malignant have been filed in association with OSIMERTINIB (TAGRISSO). This represents 0.6% of all adverse event reports for OSIMERTINIB.
165
Reports of Neoplasm malignant with OSIMERTINIB
0.6%
of all OSIMERTINIB reports
35
Deaths
17
Hospitalizations
How Dangerous Is Neoplasm malignant From OSIMERTINIB?
Of the 165 reports, 35 (21.2%) resulted in death, 17 (10.3%) required hospitalization, and 8 (4.8%) were considered life-threatening.
Is Neoplasm malignant Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for OSIMERTINIB. However, 165 reports have been filed with the FAERS database.
What Other Side Effects Does OSIMERTINIB Cause?
Death (10,423)
Malignant neoplasm progression (2,920)
Diarrhoea (1,408)
Drug resistance (1,026)
Fatigue (819)
Rash (772)
Decreased appetite (706)
Drug ineffective (627)
Dyspnoea (621)
Nausea (610)
What Other Drugs Cause Neoplasm malignant?
RANITIDINE (10,648)
ADALIMUMAB (2,028)
APIXABAN (1,772)
ETANERCEPT (1,616)
METHOTREXATE (1,041)
TOFACITINIB (1,020)
RITUXIMAB (929)
INFLIXIMAB (892)
ABATACEPT (727)
RISANKIZUMAB-RZAA (715)
Which OSIMERTINIB Alternatives Have Lower Neoplasm malignant Risk?
OSIMERTINIB vs OSPEMIFENE
OSIMERTINIB vs OSPHENA
OSIMERTINIB vs OVINE DIGOXIN IMMUNE FAB
OSIMERTINIB vs OXACILLIN
OSIMERTINIB vs OXALIPLATIN